Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear

2019-05-21 Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.

read more Link to \Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear\""

Nivolumab with ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

2019-05-15 There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores.

read more Link to \Nivolumab with ipilimumab: drug combination has added benefit in advanced renal cell carcinoma\""

Blister packaging for drugs in nursing homes: much discussed, but hardly investigated

2019-05-14 Data are lacking for arguments on the pros and cons, as the available studies examine the outpatient sector. IQWiG proposes a design for a new study.

read more Link to \Blister packaging for drugs in nursing homes: much discussed, but hardly investigated\""

Apalutamide in prostate cancer: indication of considerable added benefit

2019-05-02 Symptomatic progression is significantly retarded by this drug. This advantage clearly outweighs the disadvantages presented by some side effects.

read more Link to \Apalutamide in prostate cancer: indication of considerable added benefit\""

How NNTs can be graphically illustrated in network meta-analyses

2019-04-25 In the Journal of Clinical Epidemiology, an international team of authors discusses the possibilities and limitations of graphical representations of statements on absolute effects.

read more Link to \How NNTs can be graphically illustrated in network meta-analyses\""

Ribociclib in advanced breast cancer: survival advantages, accompanied by severe side effects

2019-04-15 Study indicates longer overall survival of postmenopausal women. However, there is a higher frequency of severe diseases of blood and lymphatic system. Overall, added benefit not proven.

read more Link to \Ribociclib in advanced breast cancer: survival advantages, accompanied by severe side effects\""

Negative pressure wound therapy: subsequently submitted manufacturer data now allow conclusions on benefit

2019-03-28 Hint and indication of benefit for primary and secondary wound healing, respectively. But studies still concealed. Comments on preliminary report “primary wound healing” possible until 29.4.

read more Link to \Negative pressure wound therapy: subsequently submitted manufacturer data now allow conclusions on benefit\""

Erenumab in migraine: indication of considerable added benefit for certain patients

2019-02-01 The first drug of a new drug class can reduce the number of headache days if other prophylactic medications have failed or have not been an option.

read more Link to \Erenumab in migraine: indication of considerable added benefit for certain patients\""

For the first time, IQWiG supported professional societies in the development of new S3 guideline

2019-01-31 Commissioned by the Federal Ministry of Health, the Institute searched for studies on vaginal (“natural”) birth and assessed them. The guideline group appreciates the high quality of the reports.

read more Link to \For the first time, IQWiG supported professional societies in the development of new S3 guideline\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No Title Type Deadline
V18-01Guideline synopsis for the DMP “type 2 diabetes” zum Vorbericht 06.06.2019
S19-01Prostate cancer screening with the PSA test zum Berichtsplan 26.06.2019

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Apalutamide (Erleada) for the treatment of prostate cancer

Apalutamide (trade name: Erleada) has been approved in Germany since January 2019 for the treatment of non-metastatic prostate cancer if conventional hormone blockers are no longer effective. This medication is an option if there is a high risk of the cancer spreading (metastasis).   read more (Link to \Apalutamide (Erleada) for the treatment of prostate cancer\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close